Incorporation of gemcitabine and cytarabine into DNA by DNA polymerase β and ligase III/XRCC1

Biochemistry

Volumn 49, Issue 23, 2010, Pages 4833-4840

  Prakasha Gowda, A S ^a   Polizzi, Joanna M ^a   Eckert, Kristin A ^a   Spratt, Thomas E ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASE EXCISION REPAIRS; CANCER CHEMOTHERAPEUTIC AGENTS; CHEMOTHERAPY TREATMENT; CYTARABINE; CYTIDINE; DNA POLYMERASE; DNA SUBSTRATES; DNA SYNTHESISS; GEMCITABINE; MODIFIED NUCLEOTIDES; NUCLEOSIDE TRIPHOSPHATES; NUCLEOTIDE ANALOGUES;

CHEMOTHERAPY; DNA; NUCLEOTIDES; POLYMERS; TUMORS;

GENES;

CYTARABINE; CYTIDINE; DNA DIRECTED DNA POLYMERASE BETA; GEMCITABINE; XRCC1 PROTEIN;

ARTICLE; CHEMICAL REACTION KINETICS; DNA DAMAGE; EXCISION REPAIR; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEADY STATE;

ANTIMETABOLITES, ANTINEOPLASTIC; CATALYSIS; CYTARABINE; DEOXYCYTIDINE; DNA DAMAGE; DNA LIGASES; DNA POLYMERASE BETA; DNA REPAIR; DNA-BINDING PROTEINS; HUMANS; KINETICS; SIGNAL TRANSDUCTION; SUBSTRATE SPECIFICITY;

EID: 77953257303     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/bi100200c     Document Type: Article

References (68)

1. Burnett, A. K., Milligan, D., Prentice, A. G., Goldstone, A. H., McMullin, M. F., Hills, R. K., and Wheatley, K. (2007) A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment Cancer 109, 1114-1124
2. Crino, L., Mosconi, A. M., Scagliotti, G., Selvaggi, G., Novello, S., Rinaldi, M., Della, G. M., Gridelli, C., Rossi, A., Calandri, C., De Marinis, F., Noseda, M., and Tonato, M. (1999) Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: a phase II trial J. Clin. Oncol. 17, 2081-2085
3. Tempero, M., Plunkett, W., Ruiz, v. H. V., Hainsworth, J., Hochster, H., Lenzi, R., and Abbruzzese, J. (2003) Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma J. Clin. Oncol. 21, 3402-3408
4. Burris, H. A., III, Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., Nelson, R., Dorr, F. A., Stephens, C. D., and Von Hoff, D. D. (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J. Clin. Oncol. 15, 2403-2413
5. Hensley, M. L., Correa, D. D., Thaler, H., Wilton, A., Venkatraman, E., Sabbatini, P., Chi, D. S., Dupont, J., Spriggs, D., and Aghajanian, C. (2006) Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning Gynecol. Oncol. 102, 270-277
6. Morandi, P. (2006) Biological agents and gemcitabine in the treatment of breast cancer Ann. Oncol. 17 (Suppl. 5) v177-v180
7. Carmichael, J. and Walling, J. (1996) Phase II activity of gemcitabine in advanced breast cancer Semin. Oncol. 23, 77-81
8. Nabhan, C., Krett, N., Gandhi, V., and Rosen, S. (2001) Gemcitabine in hematologic malignancies Curr. Opin. Oncol. 13, 514-521
9. Sallah, S., Wan, J. Y., and Nguyen, N. P. (2001) Treatment of refractory T-cell malignancies using gemcitabine Br. J. Haematol. 113, 185-187
10. Gandhi, V., Mineishi, S., Huang, P., Chapman, A. J., Yang, Y., Chen, F., Nowak, B., Chubb, S., Hertel, L. W., and Plunkett, W. (1995) Cytotoxicity, metabolism, and mechanisms of action of 2′,2′-difluorodeoxyguanosine in Chinese hamster ovary cells Cancer Res. 55, 1517-1524
11. Huang, P., Chubb, S., Hertel, L. W., Grindey, G. B., and Plunkett, W. (1991) Action of 2′,2′-difluorodeoxycytidine on DNA synthesis Cancer Res. 51, 6110-6117
12. Iwasaki, H., Huang, P., Keating, M. J., and Plunkett, W. (1997) Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells Blood 90, 270-278
13. Heinemann, V., Hertel, L. W., Grindey, G. B., and Plunkett, W. (1988) Comparison of the cellular pharmacokinetics and toxicity of 2′,2′- difluorodeoxycytidine and 1-beta- d -arabinofuranosylcytosine Cancer Res. 48, 4024-4031
14. Shao, J., Zhou, B., Chu, B., and Yen, Y. (2006) Ribonucleotide reductase inhibitors and future drug design Curr. Cancer Drug Targets 6, 409-431
15. Wang, J., Lohman, G. J. S., and Stubbe, J. (2009) Mechanism of inactivation of human ribonucleotide reductase with p53R2 by gemcitabine 5′-diphosphate Biochemistry 48, 11612-11621
16. Artin, E., Wang, J., Lohman, G. J. S., Yokoyama, K., Yu, G., Griffin, R. G., Bar, G., and Stubbe, J. (2009) Insight into the mechanism of inactivation of ribonucleotide reductase by gemcitabine 5′-diphosphate in the presence or absence of reductant Biochemistry 48, 11622-11629
17. Pourquier, P., Takebayashi, Y., Urasaki, Y., Gioffre, C., Kohlhagen, G., and Pommier, Y. (2000) Induction of topoisomerase I cleavage complexes by 1-beta- d -arabinofuranosylcytosine (ara-C) in vitro and in ara-C-treated cells Proc. Natl. Acad. Sci. U.S.A. 97, 1885-1890
18. Pourquier, P., Gioffre, C., Kohlhagen, G., Urasaki, Y., Goldwasser, F., Hertel, L. W., Yu, S., Pon, R. T., Gmeiner, W. H., and Pommier, Y. (2002) Gemcitabine (2′,2′-difluoro-2′-deoxycytidine), an antimetabolite that poisons topoisomerase I Clin. Cancer Res. 8, 2499-2504
19. Richardson, K. A., Vega, T. P., Richardson, F. C., Moore, C. L., Rohloff, J. C., Tomkinson, B., Bendele, R. A., and Kuchta, R. D. (2004) Polymerization of the triphosphates of AraC, 2′,2′-difluorodeoxycytidine (dFdC) and OSI-7836 (T-araC) by human DNA polymerase alpha and DNA primase Biochem. Pharmacol. 68, 2337-2346
20. Jiang, H. Y., Hickey, R. J., Abdel-Aziz, W., and Malkas, L. H. (2000) Effects of gemcitabine and araC on in vitro DNA synthesis mediated by the human breast cell DNA synthesome Cancer Chemother. Pharmacol. 45, 320-328
21. Fowler, J. D., Brown, J. A., Johnson, K. A., and Suo, Z. (2008) Kinetic investigation of the inhibitory effect of gemcitabine on DNA polymerization catalyzed by human mitochondrial DNA polymerase gamma J. Biol. Chem. 283, 15339-15348
22. Shi, Z., Azuma, A., Sampath, D., Li, Y. X., Huang, P., and Plunkett, W. (2001) S-phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine Cancer Res. 61, 1065-1072
23. Ewald, B., Sampath, D., and Plunkett, W. (2007) H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation Mol. Cancer Ther. 6, 1239-1248
24. Chen, Y. W., Cleaver, J. E., Hanaoka, F., Chang, C. F., and Chou, K. M. (2006) A novel role of DNA polymerase eta in modulating cellular sensitivity to chemotherapeutic agents Mol. Cancer Res. 4, 257-265
25. Liu, G. and Chen, X. (2006) DNA polymerase eta, the product of the xeroderma pigmentosum variant gene and a target of p53, modulates the DNA damage checkpoint and p53 activation Mol. Cell. Biol. 26, 1398-1413
26. Crul, M., van Waardenburg, R. C. A. M., Bocxe, S., van Eijndhoven, M. A. J., Pluim, D., Beijnen, J. H., and Schellens, J. H. M. (2003) DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin Biochem. Pharmacol. 65, 275-282
27. Pelicano, H., Carney, D., and Huang, P. (2004) ROS stress in cancer cells and therapeutic implications Drug Resist. Updates 7, 97-110
28. Kow, Y. W. (2002) Repair of deaminated bases in DNA Free Radical Biol. Med. 33, 886-893
29. Caulfield, J. L., Wishnok, J. S., and Tannenbaum, S. R. (1998) Nitric oxide-induced deamination of cytosine and guanine in deoxynucleosides and oligonucleotides J. Biol. Chem. 273, 12689-12695
30. Geller, H. M., Cheng, K. Y., Goldsmith, N. K., Romero, A. A., Zhang, A. L., Morris, E. J., and Grandison, L. (2001) Oxidative stress mediates neuronal DNA damage and apoptosis in response to cytosine arabinoside J. Neurochem. 78, 265-275
31. Conklin, K. A. (2004) Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness Integr. Cancer Ther. 3, 294-300
32. Albertella, M. R., Lau, A., and OConnor, M. J. (2005) The overexpression of specialized DNA polymerases in cancer DNA Repair 4, 583-593
33. Lamarche, B. J., Showalter, A. K., and Tsai, M. D. (2005) An error-prone viral DNA ligase Biochemistry 44, 8408-8417
34. Zhao, X., Muller, J. G., Halasyam, M., David, S. S., and Burrows, C. J. (2007) In vitro ligation of oligodeoxynucleotides containing C8-oxidized purine lesions using bacteriophage T4 DNA ligase Biochemistry 46, 3734-3744
35. Ludwig, J. (1981) A new route to nucleoside 5′-triphosphates Acta Biochim. Biophys. Acad. Sci. Hung. 16, 131-133
36. Opresko, P. L., Shiman, R., and Eckert, K. A. (2000) Hydrophobic interactions in the hinge domain of DNA polymerase beta are important but not sufficient for maintaining fidelity of DNA synthesis Biochemistry 39, 11399-11407
37. Kretulskie, A. M. and Spratt, T. E. (2006) Structure of purine-purine mispairs during misincorporation and extension by E. coli DNA polymerase I Biochemistry 45, 3740-3746
38. Nick McElhinny, S. A. and Ramsden, D. A. (2003) Polymerase mu is a DNA-directed DNA/RNA polymerase Mol. Cell. Biol. 23, 2309-2315
39. Ruiz, J. F., Juarez, R., Garcia-Diaz, M., Terrados, G., Picher, A. J., Gonzalez-Barrera, S., Fernandez de Henestrosa, A. R., and Blanco, L. (2003) Lack of sugar discrimination by human Pol mu requires a single glycine residue Nucleic Acids Res. 31, 4441-4449
40. Showalter, A. K. and Tsai, M. D. (2002) A reexamination of the nucleotide incorporation fidelity of DNA polymerases Biochemistry 41, 10571-10576
41. Roettger, M. P., Bakhtina, M., and Tsai, M. D. (2008) Mismatched and matched dNTP incorporation by DNA polymerase beta proceed via analogous kinetic pathways Biochemistry 47, 9718-9727
42. Tang, K. H., Niebuhr, M., Tung, C. S., Chan, H. C., Chou, C. C., and Tsai, M. D. (2008) Mismatched dNTP incorporation by DNA polymerase beta does not proceed via globally different conformational pathways Nucleic Acids Res. 36, 2948-2957
43. Ahn, J., Kraynov, V. S., Zhong, X., Werneburg, B. G., and Tsai, M. D. (1998) DNA polymerase beta: effects of gapped substrates on dNTP specificity, fidelity, processivity and conformational changes Biochem. J. 331, 79-87
44. Vande Berg, B. J., Beard, W. A., and Wilson, S. H. (2001) DNA structure and aspartate 276 influence nucleotide binding to human DNA polymerase beta. Implication for the identity of the rate-limiting conformational change J. Biol. Chem. 276, 3408-3416
45. DeLucia, A. M., Chaudhuri, S., Potapova, O., Grindley, N. D. F., and Joyce, C. M. (2006) The properties of steric gate mutants reveal different constraints within the active sites of Y-family and A-family DNA polymerases J. Biol. Chem. 281, 27286-27291
46. Mikita, T. and Beardsley, G. P. (1988) Functional consequences of the arabinosylcytosine structural lesion in DNA Biochemistry 27, 4698-4705
47. Bakhtina, M., Roettger, M. P., and Tsai, M. D. (2009) Contribution of the reverse rate of the conformational step to polymerase beta fidelity Biochemistry 48, 3197-3208
48. Bakhtina, M., Roettger, M. P., Kumar, S., and Tsai, M. D. (2007) A unified kinetic mechanism applicable to multiple DNA polymerases Biochemistry 46, 5463-5472
49. DeLucia, A. M., Grindley, N. D. F., and Joyce, C. M. (2003) An error-prone family Y DNA polymerase (DinB homolog from Sulfolobus solfataricus) uses a "steric gate" residue for discrimination against ribonucleotides Nucleic Acids Res. 31, 4129-4137
50. Astatke, M., Ng, K., Grindley, N. D., and Joyce, C. M. (1998) A single side chain prevents Escherichia coli DNA polymerase I (Klenow fragment) from incorporating ribonucleotides Proc. Natl. Acad. Sci. U.S.A. 95, 3402-3407
51. Yang, G., Franklin, M., Li, J., Lin, T. C., and Konigsberg, W. (2002) A conserved Tyr residue is required for sugar selectivity in a pol alpha DNA polymerase Biochemistry 41, 10256-10261
52. Bonnin, A., Lsszaro, J. M., Blanco, L., and Salas, M. (1999) A single tyrosine prevents insertion of ribonucleotides in the eukaryotic-type [phi]29 DNA polymerase J. Mol. Biol. 290, 241-251
53. Gardner, A. F. and Jack, W. E. (1999) Determinants of nucleotide sugar recognition in an archaeon DNA polymerase Nucleic Acids Res. 27, 2545-2553
54. Cases-Gonzalez, C. E., Gutierrez-Rivas, M., and Menendez-Arias, L. (2000) Coupling ribose selection to fidelity of DNA synthesis J. Biol. Chem. 275, 19759-19767
55. Pelletier, H. (1994) Polymerase structures and mechanism Science 266, 2025-2026
56. Beard, W. A. and Wilson, S. H. (1998) Structural insights into polymerase beta fidelity: hold tight if you want it right Chem. Biol. 5, R7-R13
57. Brown, T., Hunter, W. N., Kneale, G., and Kennard, O. (1986) Molecular structure of the GA base pair in DNA and its implications for the mechanism of transversion mutations Proc. Natl. Acad. Sci. U.S.A. 83, 2402-2406 (Pubitemid 16026893)
58. Gmeiner, W. H., Skradis, A., Pon, R. T., and Liu, J. (1998) Cytarabine-induced destabilization of a model Okazaki fragment Nucleic Acids Res. 26, 2359-2365
59. Schweitzer, B. I., Mikita, T., Kellogg, G. W., Gardner, K. H., and Beardsley, G. P. (1994) Solution structure of a DNA dodecamer containing the anti-neoplastic agent arabinosylcytosine: combined use of NMR, restrained molecular dynamics, and full relaxation matrix refinement Biochemistry 33, 11460-11475
60. Pieters, J. M., de Vroom, E., van der Marel, G. A., van Boom, J. H., Koning, T. M., Kaptein, R., and Altona, C. (1990) Hairpin structures in DNA containing arabinofuranosylcytosine. A combination of nuclear magnetic resonance and molecular dynamics Biochemistry 29, 788-799
61. Pieters, J. M., de Vroom, E., van der Marel, G. A., van Boom, J. H., and Altona, C. (1989) Conformational consequences of the incorporation of arabinofuranosylcytidine in DNA. An NMR study of the DNA fragments d(CGCTAGCG) and d(CGaCTAGCG) in solution Eur. J. Biochem. 184, 415-425
62. Smart, B. E. (2001) Fluorine substituent effects (on bioactivity) J. Fluorine Chem. 109, 3-11
63. Konerding, D., James, T. L., Trump, E., Soto, A. M., Marky, L. A., and Gmeiner, W. H. (2002) NMR structure of a gemcitabine-substituted model Okazaki fragment Biochemistry 41, 839-846
64. Lee, S., Bowman, B. R., Ueno, Y., Wang, S., and Verdine, G. L. (2008) Synthesis and structure of duplex DNA containing the genotoxic nucleobase lesion N7-methylguanine J. Am. Chem. Soc. 130, 11570-11571
65. Bowman, B. R., Lee, S., Wang, S., and Verdine, G. L. (2008) Structure of the E. coli DNA glycosylase AlkA bound to the ends of duplex DNA: a system for the structure determination of lesion-containing DNA Structure 16, 1166-1174
66. Osheroff, W. P., Jung, H. K., Beard, W. A., Wilson, S. H., and Kunkel, T. A. (1999) The fidelity of DNA polymerase beta during distributive and processive DNA synthesis J. Biol. Chem. 274, 3642-3650
67. Bhagwat, A. S., Sanderson, R. J., and Lindahl, T. (1999) Delayed DNA joining at 3′ mismatches by human DNA ligases Nucleic Acids Res. 27, 4028-4033
68. Pascal, J. M., OBrien, P. J., Tomkinson, A. E., and Ellenberger, T. (2004) Human DNA ligase I completely encircles and partially unwinds nicked DNA Nature 432, 473-478